Sector News

Categories

Borderless Insights

Image
Negotiating Terms with a New Employer
Image
Beyond Flowers and Platitudes: Reclaiming the Essence of International Women’s Day
Image
Visionary or ‘Stuck-in-the-Mud’? Where are you on Workplace Flexibility?

Actavis aims to add Allergan CEO to its board: sources

January 16, 2015
Life sciences
(Reuters) – Allergan Inc (AGN.N) Chief Executive David Pyott is close to joining the board of directors of Actavis Plc (ACT.N), which reached a deal to buy the Botox-maker for $66 billion in November, three people familiar with the matter said on Thursday.
 
Actavis CEO Brent Saunders is trying to recruit Pyott to join the board and is working through corporate governance issues, the people said, asking not to be named because the matter is private.
 
They said Saunders described the plan at a small meeting with shareholders during the J.P. Morgan Healthcare conference in San Francisco this week. One investor who attended the meeting told Reuters that adding Pyott to the board could lend more credibility to Actavis’s efforts to integrate Allergan into its operations.
 
Actavis said in November that two members of the Allergan board would be invited to join the board of the combined company, but did not specify what Pyott’s new role would be.
 
If Pyott were to join the Actavis board, he would be considered a non-independent board member because of his ties to the acquired company, bringing the number of non-independent board members at Actavis to three. They include Saunders and Executive Chairman Paul Bisaro.
 
While proxy advisory firms like ISS do not have guidelines on the precise number of non-independent directors they like to see on a board, outsiders typically view a board more favorably if it has fewer non-independent directors.
 
Actavis said in December it would replace the majority of Allergan’s top executives once the deal closes, with the exception of Allergan president Doug Ingram who will serve as a special adviser to Saunders.
 
The deal, which thwarted a seven months-long hostile attempt by Valeant Pharmaceuticals Inc (VRX.TO) to buy Allergan, is expected to close in the second quarter of this year.
 
Officials for Actavis and Allergan declined to comment.
 
(Reporting by Caroline Humer and Olivia Oran; Editing by Michele Gershberg and David Gregorio)

comments closed

Related News

April 26, 2024

Former Bristol Myers CEO tapped as Novartis’ next board chair

Life sciences

Giovanni Caforio, the former CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, which on Tuesday proposed the pharmaceutical industry veteran as its pick to replace Joerg Reinhardt in the role next year. Reinhardt has served as Novartis’ chair since 2013 and plans to retire when his 12-year term ends in 2025.

Read more
April 26, 2024

GE HealthCare launches voice-activated, AI-powered ultrasound machines for women’s health

Life sciences

GE HealthCare has raised the curtain on two ultrasound systems equipped with artificial intelligence programs designed to assist in diagnosing conditions in women’s health, including obstetric exams. The Voluson Signature 20 and 18 imaging systems include AI tools capable of automatically identifying and annotating measurements of fetal anatomy.

Read more
April 26, 2024

Scientists reveal new method that could reduce waste from drug manufacturing

Life sciences

Scientists from the University of Edinburgh’s School of Chemistry have revealed a new sustainable method of manufacturing complex molecules that could reduce waste produced during drug production. The method published in Nature Chemistry could help to prevent severe side effects caused by drugs that can exist as enantiomers.

Read more
More news

How can we help you?

We're easy to reach